Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Colon, Rectal and Bowel Cancer (Colorectal Cancer) article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Carcinoembryonic antigen (CEA) is a glycoprotein, which is present in normal mucosal cells but increased amounts are associated with adenocarcinoma, especially colorectal cancer. CEA therefore has a role as a tumour marker. Sensitivity and specificity are low, however, so it is of more use for monitoring than for screening or diagnosis.
CEA levels are useful in assessing prognosis (with other factors), detecting recurrence (especially for disease that cannot be evaluated by other means) and monitoring treatment in people with colorectal cancer. CEA is particularly recommended for postoperative follow-up of patients with colorectal cancer.
Conditions which may have elevated CEA
CEA may be elevated in colorectal cancer, which is where it is most clinically useful. However, it may also be elevated in a wide variety of other malignant and benign conditions.
Malignant conditions which may have elevated CEA include:
- Colorectal cancer.
- Breast cancer.
- Lung cancer.
- Cancer of the stomach.
- Cancer of the oesophagus.
- Cancer of the pancreas.
- Medullary thyroid carcinoma.
- Skeletal metastases (may occasionally be a useful screening tool for distinguishing skeletal metastases of tumours above from primary bone or haematological malignancy).
Non-malignant conditions which may have elevated CEA include:
- Non-malignant liver disease, including cirrhosis, chronic active hepatitis, viral hepatitis and obstructive jaundice.
- Chronic kidney disease.
- Inflammatory bowel disease (Crohn's disease; ulcerative colitis).
- Irritable bowel syndrome.
- Respiratory diseases - eg, pleural inflammation, pneumonia.
Individual laboratory normal ranges vary but CEA level is usually deemed to be normal at 2.5-5 μg/L. Increasing levels of CEA suggestive of active disease may be more clinically helpful than absolute level. Levels exceeding 10 μg/L are rarely due to benign disease or the moderate elevation that may occur due to smoking.
Sensitivity in early-stage colorectal cancer is very low and increases with the stage of the disease. Studies reporting sensitivity vary in the cut off for what constitutes a normal CEA level so results are varied. Using a cut-off point of 5 μg/L, the proportions of patients with increased values are 3%, 25%, 45% and 65% for patients with Dukes' A, B, C and D disease respectively. Around 72% of cases with unresectable or metastatic disease have elevated CEA levels.
Indications for CEA measurement
Due to the low sensitivity and specificity of the CEA test, it is not recommended that it be used for screening of healthy individuals or for the diagnosis of early colorectal cancer. A CEA level should be ordered only after malignancy has been confirmed.
- The CEA test is of much more use in determining prognosis than it is as an early diagnostic test for colon cancer.
- CEA levels are more likely to be elevated in advanced disease.
- Monitoring treatment:
- The major role for CEA levels is in following patients for relapse after intended curative treatment of colorectal cancer.
- CEA levels typically return to normal within four to six weeks after successful surgical resection. The CEA level can also be used to assess the response to chemotherapy.
- The National Institute for Health and Care Excellence (NICE) recommends that for people who have had potentially curative surgical treatment for non-metastatic colorectal cancer, follow-up for detection of local recurrence and distant metastases for the first three years should include CEA and CT scan of the chest, abdomen and pelvis.
- Clinical trials have shown improvement in survival after five years in patients who underwent CEA monitoring as part of post-treatment management.
- However, a Cochrane review found no overall survival benefit for intensifying the follow-up of patients after curative surgery for colorectal cancer. More participants were treated with salvage surgery with curative intent in the intensive follow-up groups, but this was not associated with improved survival. Harms related to intensive follow-up and salvage therapy were not well reported.
- Normal levels do not necessarily indicate that recurrence has not occurred.
Similar considerations apply to the diagnosis of breast cancer. The sensitivity of CEA is too low for it to be used as a primary diagnostic test. Although the prognosis for operable breast cancers is reportedly worse if serum CEA and cancer antigen 15-3 (CA15-3) levels are above normal, the usefulness of this prognosis is limited due to the low sensitivity and specificity. In addition, the optimal cut-off levels remain unknown.
Some studies have shown that, in conjunction with other tumour markers (CA27.29, tissue polypeptide antigen and especially CA 15-3), CEA may however be helpful in the following:
- Disease surveillance.
- Identifying patients with skeletal metastases.
- Predicting response to chemotherapy.
It is not recommended in the routine surveillance of breast cancer and should not be used in isolation for monitoring in advanced disease.
Further reading and references
Hall C, Clarke L, Pal A, et al; A Review of the Role of Carcinoembryonic Antigen in Clinical Practice. Ann Coloproctol. 2019 Dec35(6):294-305. doi: 10.3393/ac.2019.11.13. Epub 2019 Dec 31.
Sturgeon CM, Lai LC, Duffy MJ; Serum tumour markers: how to order and interpret them. BMJ. 2009 Sep 22339:b3527. doi: 10.1136/bmj.b3527.
Tsukushi S, Katagiri H, Kataoka T, et al; Serum tumor markers in skeletal metastasis. Jpn J Clin Oncol. 2006 Jul36(7):439-44. Epub 2006 Jun 30.
Sturgeon CM, Duffy MJ, Stenman UH, et al; National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec54(12):e11-79. doi: 10.1373/clinchem.2008.105601.
Fakih MG, Padmanabhan A; CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park). 2006 May20(6):579-87
Levy M, Visokai V, Lipska L, et al; Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma. 200855(2):138-42.
Colorectal cancer (management in people aged 18 and over); NICE Guidance (January 2020)
Jeffery M, Hickey BE, Hider PN; Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2019 Sep 49:CD002200. doi: 10.1002/14651858.CD002200.pub4.
Hara M, Kanemitsu Y, Hirai T, et al; Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study. Dis Colon Rectum. 2008 Nov51(11):1675-80.
Imamura M, Morimoto T, Nomura T, et al; Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World J Surg Oncol. 2018 Feb 1216(1):26. doi: 10.1186/s12957-018-1325-6.
Brooks M; Breast cancer screening and biomarkers. Methods Mol Biol. 2009472:307-21.
Duffy MJ; Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006 Mar52(3):345-51. Epub 2006 Jan 12.
Yonemori K, Katsumata N, Noda A, et al; Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. J Cancer Res Clin Oncol. 2008 Nov134(11):1199-206. Epub 2008 Jun 5.